BioCancell Ltd (Israel) Financial Indicators Patterns

BICL -- Israel Stock  

ILS 1,426  32.00  2.19%

We suggest you to use BioCancell Ltd fundamental analysis to see if markets are presently mispricing the company. In plain English you can use it to find out if BioCancell Ltd is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found twenty-four available fundamental indicators for BioCancell Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all BioCancell Ltd fundamentals including its EBITDA, Cash and Equivalents, Current Ratio, as well as the relationship between Net Income and Cash per Share . Use BioCancell Ltd to protect your portfolios against small markets fluctuations. The stock experiences unexpected downward movement. The market is reacting to new fundamentals. Check odds of BioCancell Ltd to be traded at S1368.96 in 30 days.

Chance of Financial Distress

BioCancell Ltd has more than 54 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

BioCancell Ltd Company Summary

BioCancell Ltd competes with Gazit Globe, Jerusalem Economy, Ratio Oil, Electra Ltd, and Matrix IT. BioCancell Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to treat cancer-related diseases. The company was founded in 2004 and is based in Jerusalem, Israel. BioCancell Ltd is traded on Tel Aviv Stock Exchange in Israel.

BioCancell Ltd Price to Book vs Cash per Share

BioCancell Ltd is number one stock in price to book category among related companies. It is rated below average in cash per share category among related companies . The ratio of Price to Book to Cash per Share for BioCancell Ltd is about  1,403 

BioCancell Ltd Market Fundamentals

 Change(%) 2.19%

BioCancell Ltd April 25, 2019 Opportunity Range

Check also Trending Equities. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.